BusinessEsperion to Participate in Fireside Chat at the Deutsche Bank 43rd Annual Health Care ConferenceBy Nasdaq OMXMay 4, 2018, 8:01 PM UTC
BusinessEsperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial ResultsBy Nasdaq OMXMay 2, 2018, 11:40 AM UTC
BusinessEsperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic AcidBy Nasdaq OMXMay 2, 2018, 11:31 AM UTC
BusinessEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)By Nasdaq OMXApr 13, 2018, 8:30 PM UTC
BusinessEsperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with HypercholesterolemiaBy Nasdaq OMXMar 27, 2018, 11:30 AM UTC
BusinessEsperion to Participate in Fireside Chat at March 2018 Investor ConferencesBy Nasdaq OMXMar 7, 2018, 9:02 PM UTC
BusinessEsperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic AcidBy Nasdaq OMXMar 7, 2018, 12:30 PM UTC
BusinessEsperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)By Nasdaq OMXFeb 23, 2018, 9:30 PM UTC
